Daprodustat is a Small Molecule owned by GSK, and is involved in 37 clinical trials, of which 35 were completed, and 2 are ongoing.

Daprodustat acts by inhibiting hypoxia-inducible factor (HIF)-prolyl hydroxylases. Hypoxia-inducible factor (HIF), a heterodimeric nuclear factor, is a crucial intermediate in these defensive mechanisms. HIF is constitutively transcribed and translated. Its stability is drastically reduced by the oxygen dependent enzymatic hydroxylation of proline residues by prolyl hydroxylases (PHD). Hence these prolyl hydroxylase (PH) inhibitors selectively stimulate HIF-2 and HIF-1 mediated erythropoiesis for the treatment of anemia. The alpha subunit of HIF-1 is a target for prolyl hydroxylation by HIF prolyl-hydroxylase, which makes HIF-1 a target for degradation by an E3 ubiquitin ligase, leading to quick degradation by the proteasome.

The revenue for Daprodustat is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Daprodustat NPV Report.

Daprodustat is originated and owned by GSK. Kyowa Kirin is the other company associated in development or marketing of Daprodustat.

Daprodustat Overview

Daprodusta (Duvroq) is an anti anemic agent. It is formulated as film coated tablets for oral route of administration. Duvroq indicated for the treatment of anaemia due to chronic kidney disease in adult patients not on dialysis and on dialysis.

The drug candidate can be applied topically as an ointment. It is a prolyl hydroxylase inhibitor.The drug candidate was also under development for the treatment of peripheral arterial disease (PAD)/peripheral vascular disease (PVD), ischemic events in patients undergoing thoracic aortic aneurysm repair, diabetic foot ulcer, wounds and tendon injuries.

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Daprodustat

Report Segments
  • Innovator (NME)
Drug Name
  • Daprodustat
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Hematological Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Companies
  • Sponsor Company: GSK
  • Originator: GSK
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.